IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH

Core Insights - IBA has announced the acquisition of PhantomX GmbH, enhancing its healthcare diagnostics and therapeutic systems with AI quality assurance capabilities [1][3] Company Overview - IBA (Ion Beam Applications S.A.) is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry [5] - The company is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people worldwide [5] - IBA is listed on the EURONEXT stock exchange and is a certified B Corporation, meeting high social and environmental performance standards [6] PhantomX GmbH - Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz, PhantomX is recognized for developing realistic anthropomorphic phantoms and advanced quality assurance technologies for medical imaging [2] - The company focuses on AI validation in medical imaging and provides tools for AI-enhanced clinical solutions [2] Strategic Implications - The acquisition of PhantomX is expected to complement IBA's Clinical Workflow Solutions in Radiation Therapy and Medical Imaging, accelerating innovation through simulation and AI-driven technologies [3] - This merger aims to expand PhantomX's technology into new markets, contributing to the development of intelligent and effective medical solutions [3]